Graham Capital Management L.P. Has $2.74 Million Position in Qiagen N.V. $QGEN

Key Points

• Graham Capital Management L.P. increased its stake in Qiagen N.V. by 92.7% in the first quarter, acquiring an additional 32,774 shares and bringing its total holdings to 68,114 shares valued at approximately $2.735 million.
• Analysts have set a consensus price target of $49.69 for Qiagen, with Barclays issuing an "overweight" rating and a target of $55.00, while Bank of America and UBS have upped their targets to $53.00 and $50.00, respectively.
• Qiagen reported quarterly earnings of $0.60 per share, matching expectations, and a revenue of $533.54 million, exceeding analyst projections of $523.97 million.

Graham Capital Management L.P. boosted its stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 92.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,114 shares of the company's stock after acquiring an additional 32,774 shares during the period. Graham Capital Management L.P.'s holdings in Qiagen were worth $2,735,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in QGEN. Tower Research Capital LLC TRC increased its stake in Qiagen by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after acquiring an additional 2,204 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Qiagen by 23.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 142,794 shares of the company's stock worth $6,359,000 after acquiring an additional 27,518 shares during the period. The Manufacturers Life Insurance Company increased its stake in Qiagen by 3.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 96,482 shares of the company's stock worth $4,322,000 after acquiring an additional 2,832 shares during the period. Northern Trust Corp increased its stake in Qiagen by 29.5% during the 4th quarter. Northern Trust Corp now owns 1,250,712 shares of the company's stock worth $55,694,000 after acquiring an additional 285,265 shares during the period. Finally, AQR Capital Management LLC increased its stake in Qiagen by 40.9% during the 4th quarter. AQR Capital Management LLC now owns 105,303 shares of the company's stock worth $4,689,000 after acquiring an additional 30,571 shares during the period. Institutional investors own 70.00% of the company's stock.

Qiagen Price Performance

Shares of NYSE QGEN traded up $0.30 during mid-day trading on Thursday, hitting $47.00. 835,598 shares of the stock traded hands, compared to its average volume of 1,395,714. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a market cap of $10.45 billion, a PE ratio of 27.77, a price-to-earnings-growth ratio of 2.57 and a beta of 0.64. The firm has a 50 day simple moving average of $48.68 and a two-hundred day simple moving average of $44.25.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same quarter last year, the business posted $0.55 EPS. Qiagen's revenue for the quarter was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Bank of America raised their price objective on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. UBS Group lifted their price target on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Barclays started coverage on Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.